Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 10/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6705283 | 0.87 | ADRB2 (0.50) | ADRB2ADRB1ADRB3CYP1A2CYP2D6 | |
| SCHEMBL5353906 | 0.87 | ADRB2 (0.39) | ADRB2ADRB3TDP1 | |
| SCHEMBL5353360 | 0.87 | ADRB2 (0.39) | ADRB2ADRB3TDP1 | |
| SCHEMBL5356669 | 0.84 | ADRB2 (0.62) | ADRB2ADRB3 | |
| SCHEMBL5354167 | 0.82 | ADRB2 (0.52) | ADRB2ADRB3 | |
| SCHEMBL5354160 | 0.82 | ADRB2 (0.52) | ADRB2ADRB3 | |
| SCHEMBL5353356 | 0.79 | ADRB2 (0.41) | ADRB2ADRB1ADRB3CYP1A2CYP2D6 | |
| SCHEMBL2201260 | 0.78 | ADRB3 (0.44) | ADRB2ADRB1ADRB3 | |
| SCHEMBL13900642 | 0.77 | ADRB2 (0.50) | ADRB2ADRB1ADRB3CYP1A2CYP2D6 | |
| SCHEMBL1380662 | 0.76 | ADRB3 (0.43) | ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127733-A1 | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127733-A1 | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions | ADRB1, ADRA1A, ADRA1D | ADRB2 5/4885ADRB1 1/4885ADRB3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.